Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus NOROXIN.
FLOXIN IN DEXTROSE 5% vs NOROXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
400 mg intravenously every 12 hours.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic